Form 4: Sensei Biotherapeutics Insider Sells Shares

James Peyer, a Director and 10% owner of Sensei Biotherapeutics, reported multiple sales of common stock totaling 6,612 shares, alongside the exercise of 395 stock options.

Summary

• James Peyer, a Director and 10% owner of Sensei Biotherapeutics, Inc. (SNSE), reported transactions involving the company's common stock.
• On December 8, 2025, Peyer sold 3,105 shares at a weighted average price of $8.59, with prices ranging from $8.50 to $9.00.
• On December 9, 2025, Peyer sold an additional 2,666 shares at a weighted average price of $7.95, with prices ranging from $7.80 to $8.33.
• Also on December 9, 2025, Peyer exercised 395 stock options at an exercise price of $6.40.
• Immediately following the option exercise on December 9, 2025, Peyer sold 395 shares at $8.04 and an additional 446 shares at a weighted average price of $7.92, with prices ranging from $7.91 to $7.95.
• The total number of shares sold across these transactions was 6,612, while 395 shares were acquired through option exercise.
• Following these transactions, the beneficial ownership of shares held indirectly by Cambrian Biopharma Inc. decreased from 158,254 to 155,142.
• Peyer is the Chief Executive Officer of Cambrian Biopharma Inc., which holds these shares, and disclaims beneficial ownership.

Sentiment

Score: 3

Explanation: The filing reports significant insider selling by a Director and 10% owner, James Peyer, totaling 6,612 shares. While some options were exercised, the corresponding shares were immediately sold, indicating a reduction in exposure rather than an increase. This activity is generally perceived as a negative signal by the market.

Positives

• Exercise of 395 stock options at $6.40 indicates a potential gain given the subsequent sale prices were higher ($8.04, $7.92).

Negatives

• Significant insider selling of 6,612 shares over two days by a Director and 10% owner, James Peyer.
• The sales occurred at declining weighted average prices, from $8.59 on December 8, 2025, to $7.95 and $7.92 on December 9, 2025.

Future Outlook

No forward-looking statements or guidance are provided in this Form 4 filing, which is solely for reporting insider transactions.

Industry Context

This Form 4 filing reports routine insider transactions and does not provide information relevant to broader industry trends or competitive analysis.

Comparison to Industry Standards

• This filing reports insider trading activity, which is not typically compared to global industry benchmarks or specific comparable companies/projects. The significance lies in the volume and timing of the insider's transactions relative to the company's stock performance and internal developments.

Related Party Transactions

• The shares are held indirectly by Cambrian Biopharma Inc., where James Peyer serves as Chief Executive Officer. Peyer may direct the voting and disposition of these shares, subject to Cambrian's Board approval, but disclaims beneficial ownership. This structure represents a related party relationship concerning the beneficial ownership of the shares.

Stakeholder Impact

• Shareholders may perceive the insider selling by a Director and 10% owner as a lack of confidence in the company's near-term prospects, potentially leading to negative sentiment and downward pressure on the stock price.
• Employees, customers, suppliers, and creditors are unlikely to be directly impacted by these specific insider trading disclosures, though broader market reaction could indirectly affect company morale or perception.

Key Dates

Recommendation

The significant insider selling by James Peyer, a Director and 10% owner, particularly the net reduction in beneficial ownership and the immediate sale of shares acquired through option exercise, suggests a lack of conviction or a desire to reduce exposure. This action, especially by a substantial stakeholder, typically signals potential headwinds or a belief that the stock is fully valued or overvalued, prompting a 'sell' recommendation for investors.

Keywords

Sensei Biotherapeutics, SNSE, Insider Trading, Form 4, Stock Sale, Option Exercise, James Peyer, Cambrian Biopharma, Beneficial Ownership